The directors of Thor Mining Plc ( Thor or the Company ) (AIM, ASX: THR, OTCQB: THORF), the diversified resource company, are pleased to provide an update to the Mineral Resource Estimate of its 100% owned critical minerals tungsten asset, the Molyhil Project ( Molyhil ), in the Northern Territory of Australia. Highlights: § The Molyhil Mineral Resource Estimate now comprises Measured, Indicated, and Inferred Mineral Resources totalling 4.4 million tonnes at 0.27% WO
3 (Tungsten trioxide), 0.10% Mo (Molybdenum), 0.05% Cu (Copper) and 17.75% Fe (Iron) using a 0.07% WO
3 cut-off (Table A). § Concurrent 3D geological modelling identifies priority drill targets to increase resource. § New exploration targets identified near the existing resource.
About Thor Mining PLC Thor Mining PLC (AIM, ASX: THR; OTCQB: THORF) is a diversified resource company quoted on the AIM Market of the London Stock Exchange, ASX in Australia and OTCQB Market in the United States. The Company is advancing its diversified portfolio of precious, base, energy and strategic metal projects across USA and Australia. Its focus is on progressing its copper, gold, uranium and vanadium projects, while seeking investment/JV opportunities to develop its tungsten assets. Thor owns 100% of the Ragged Range Project, comprising 92 km
2 of exploration licences with highly encouraging early stage gold and nickel results in the Pilbara region of Western Australia, for which drilling is planned in the first half of 2021.
KKR in talks to pick up 53% stake in Vini Cosmetics indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.
c. $60m Funding Commitment by Brazilian government for Clinical Development and Commercialisation of PDS Consortium s COVID-19 Vaccine London, UK - 11 March 2021 - NetScientific plc (AIM: NSCI), the life sciences and sustainability technology investment and commercialisation Group, announces that PDS Biotech s proprietary Versamune®T-cell activating technology, today announced that its COVID-19 vaccine consortium jointly run by PDS consisting of Farmacore Biotechnology and Blanver Farmoquímica, has received a commitment from the Secretary for Research and Scientific Training of the Ministry of Science, Technology and Commercialisation of Brazil ( MCTI ) to fund up to approximately US$60 million to support the clinical development and commercialization of a novel, Versamune®-based, second generation COVID-19 vaccine in Brazil.
Netscientific PLC (AIM:NSCI) | RNS | NetScientific PLC proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.